Management of Adverse Events Due to Cyclin-Dependent Kinase 4/6 Inhibitors

Area of Science:

• Oncology
• Pharmacology

Background:

• Cyclin-dependent kinase (CDK) 4/6 inhibitors are a cornerstone in treating hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer.
• These inhibitors have demonstrated a significant improvement in efficacy when combined with endocrine-based treatments, effectively doubling treatment outcomes.

Purpose of the Study:

• To provide a concise overview of the established efficacy data for CDK4/6 inhibitors.
• To summarize recommended clinical monitoring protocols for patients undergoing treatment with CDK4/6 inhibitors.
• To discuss the clinical management strategies for prevalent treatment-emergent adverse events associated with these therapies.

Main Methods:

• Review of existing clinical trial data on CDK4/6 inhibitor efficacy.
• Compilation of current guidelines for patient monitoring during CDK4/6 inhibitor therapy.
• Analysis of literature concerning the management of common adverse events and drug interactions.

Main Results:

• CDK4/6 inhibitors (palbociclib, ribociclib, abemaciclib) are effective oral agents in HR+, HER2- metastatic breast cancer.
• Key adverse events include neutropenia, liver function abnormalities, QTc interval prolongation, and diarrhea.
• Understanding and managing these toxicities, alongside drug interactions, is crucial for optimal patient care.

Conclusions:

• CDK4/6 inhibitors represent a significant advancement in HR+, HER2- metastatic breast cancer treatment.
• Effective patient monitoring and proactive management of side effects are essential for maximizing therapeutic benefit and patient safety.
• This review synthesizes current knowledge to guide clinicians in the optimal use of these agents.